GAMMA Investing LLC Acquires 1,213 Shares of Mesoblast Limited (NASDAQ:MESO)

GAMMA Investing LLC boosted its stake in shares of Mesoblast Limited (NASDAQ:MESO) by 22.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,711 shares of the company’s stock after acquiring an additional 1,213 shares during the quarter. GAMMA Investing LLC’s holdings in Mesoblast were worth $133,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its holdings in shares of Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after purchasing an additional 26,959 shares during the period. Marshall Wace LLP bought a new stake in Mesoblast in the second quarter worth $562,000. Signaturefd LLC boosted its stake in Mesoblast by 128.7% during the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after buying an additional 3,099 shares during the period. Rathbones Group PLC bought a new position in Mesoblast during the second quarter valued at $95,000. Finally, Creative Planning purchased a new stake in shares of Mesoblast in the third quarter valued at $147,000. 1.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently commented on MESO. Jefferies Financial Group cut shares of Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Tuesday, September 24th. Finally, Piper Sandler increased their price target on Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a report on Thursday, December 19th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $13.50.

Mesoblast Stock Down 4.0 %

NASDAQ MESO opened at $17.18 on Friday. Mesoblast Limited has a 12 month low of $1.61 and a 12 month high of $22.00. The company’s 50-day moving average price is $12.90 and its 200-day moving average price is $9.33. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.